<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395707</url>
  </required_header>
  <id_info>
    <org_study_id>FVF3423s</org_study_id>
    <nct_id>NCT00395707</nct_id>
  </id_info>
  <brief_title>Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration</brief_title>
  <official_title>Phase I Study Of Intravitreal Ranibizumab (Lucentis) For The Treatment Of Stage 1 And 2 Retinal Angiomatous Proliferations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The National Retina Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The National Retina Institute</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety &amp; efficacy of ranibizumab for
      the treatment of retinal angiomatous proliferation secondary to age related macular
      degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a phase I/II open label interventional case series. Twenty patients with
      retinal angiomatous proliferation will be randomized to receive intravitreal ranibizumab at a
      dose of 0.3mg/0.05 ml or 0.5mg/0.05 ml. Patients will receive ranibizumab via a pars plana
      injection on a monthly basis for a total duration of therapy of 12 months. Patients will be
      followed for a complete 12-month treatment course.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with stabilization of visual acuity, vision loss of &lt; 15 letters</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who gain at least 15 letters in the best corrected visual acuity score at 6 and 12 months compared to baseline</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of ocular adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of non-ocular adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in vital signs</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the systemic and local safety of ranibizumab (0.3mg or 0.5mg) in patients with RAP lesions</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of ranibizumab (0.3mg or 0.5mg) on time to improvement in retinal thickness by OCT</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of ranibizumab (0.3mg or 0.5 mg) on leakage from RAP lesions by Fluorescein angiography</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static / high speed ICG appearance to assess the impact of ranibizumab (0.3mg or 0.5mg) on persistence / recurrence of RAP lesion and monitor for development of retinal-choroidal anastomoses</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of ranibizumab (0.3mg or 0.5mg) on development of retinal-choroidal anastomoses as determined on clinical examination and high speed ICG</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of ranibizumab (0.3mg or 0.5mg) on development of subretinal fibrosis as determined by clinical examination</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lucentis 0.3mg/0.05 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lucentis 0.5mg/0.05 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <description>0.3mg/0.05 ml or 0.5mg/0.05 ml</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Ranibizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>0.3mg/0.05 ml or 0.5mg/0.05 ml</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab (Lucentis)</intervention_name>
    <description>0.3mg/0.05 ml intravitreally</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ranibizumab</other_name>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab (Lucentis)</intervention_name>
    <description>0.5mg/0.05 ml</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Ranibizumab</other_name>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          -  Age &gt; 50 years

          -  Definite characteristic signs of age related macular degeneration including drusen

          -  Presence of retinal angiomatous proliferation as determined by clinical signs (intra
             retinal hemorrhage, retinal edema, cystic retinal edema) and angiography (occult
             leakage on fluorescein angiography, hot spot on static ICG, visible RAP lesion of high
             speed ICG)

        Exclusion Criteria:

          -  Prior treatment with verteporfin, external-beam radiation therapy, or transpupillary
             thermotherapy in the study eye (predominantly classic CNV can however only be included
             if the subject had up to 3 prior PDT treatments)

          -  Treatment with verteporfin in the non-study eye less than 7 days preceding Day 0

          -  Previous participation in a clinical trial (for either eye) involving anti angiogenic
             drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)

          -  Previous subfoveal focal laser photocoagulation involving the foveal center in the
             study eye

          -  Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month
             preceding Day 0

          -  History of vitrectomy, submacular surgery, or other surgical intervention for AMD in
             the study eye

          -  Previous participation in any studies of investigational drugs within 1 month
             preceding Day 0 (excluding vitamins and minerals)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Retina Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Retina Institute</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Retina Institute</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2006</study_first_submitted>
  <study_first_submitted_qc>November 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2006</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>T. Mark Johnson, MD</name_title>
    <organization>National Retina Institute</organization>
  </responsible_party>
  <keyword>Macular Degeneration</keyword>
  <keyword>Age Related Macular Degeneration</keyword>
  <keyword>Retinal Angiomatous Proliferations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

